| Abstrakt: |
Despite advances in diagnostic techniques and treatments, cancer remains one of the leading causes of death worldwide.Therefore, finding new biomarkers and therapeutic targets is crucial for improving the diagnosis and treatment of human cancer.LncRNA Linc00173 is a newly identified tumor marker, and in this study, we aimed to explore the relationship between Linc00173 and clinicopathological features and patient prognosis. By using The Cochrane Library, EMbase, Web of Science, PubMed, OVID, we conducted a complete and thorough literature search from its inception to November 10, 2022.Meta-analysis was performed using Stata SE16.0 software. Nine studies involving 1102 patients were included.Meta-analysis showed that the overexpression of Linc00173 was significantly associated with poorer OS (HR = 1.76,95%CI:1.36–2.26, P < 0.001) and shorter DFS (HR = 1.89, 95%CI:1.49–2.40,P < 0.001),and was significantly associated with gender (male) (OR = 1.31,95% CI:1.01–1.69, P = 0.042), tumor size (large) (OR = 1.34,95% CI:1.01–1.78, P = 0.045), and lymph node metastasis (positive) (OR = 1.72,95% CI:1.03–2.88, P = 0.038). Overexpression of Linc00173 is associated with poor prognosis in cancer patients and is a potential prognostic biomarker and therapeutic target. [ABSTRACT FROM AUTHOR] |
Full text from SpringerLink